Merck has delivered exceptional performance, trading near its 52-week high of $123.33 with a remarkable 59% gain over six months and 42% over the past year. The stock's momentum is strong, sitting well above its 50-day moving average of $108. At a P/E of 14.88 with EPS of $8.16, Merck offers compelling value relative to pharma peers.
The bull case centers on Keytruda, the world's top-selling drug, along with a diversified pipeline spanning oncology, vaccines, and animal health. Merck's acquisition strategy (notably Prometheus Biosciences and recent deals) strengthens its post-Keytruda outlook. Financial health remains robust with consistent free cash flow generation.
The bear case involves Keytruda's patent cliff around 2028, which represents roughly 50% of pharmaceutical revenue. Pipeline execution risk and pricing pressures from potential Medicare negotiations add uncertainty. While Merck has raised its dividend for over a decade, the yield remains modest compared to true dividend aristocrats.
Overall, Merck represents a well-managed pharmaceutical giant with near-term strength but meaningful long-term transition risk that investors should monitor closely.
Merck stands as a formidable player in the global healthcare landscape, anchored by its dominant oncology franchise, particularly Keytruda, and a resilient animal health business. Trading near its 52-week high of $122.66, the stock has shown significant momentum, currently sitting well above its 50-day moving average. A P/E ratio of 25.07 suggests a premium valuation compared to some industry peers, reflecting high market expectations for its pipeline execution and recent earnings growth. While the company boasts strong cash flows and solid fundamentals, the primary risk remains its heavy revenue concentration in Keytruda and the looming patent cliff later this decade. Investors must weigh this concentration risk against Merck's aggressive M&A strategy and pipeline diversification. Overall, Merck represents a high-quality defensive holding, though the current valuation demands successful clinical outcomes to justify further upside.